I certainly hope not. I think there was sincerity around understanding the needs of Canadians with rare diseases. The money's there that was put into the budget, we've been assured. We are extremely concerned though that it is not coming out. Again, as I said, we've seen that the majority of that money, $1.4 billion out of $1.5 billion, is to be allocated through bilateral agreements.
This is, again, what we're hearing in pharmacare. What we know is that, well over a year later, none of these agreements have been put in place. We don't even know if there have been discussions around them. Whether it's just bureaucracy, whether it's just the cumbersome nature of the process, whether it's really hard to get provinces to agree, I don't know. However, this is not the way it's needed to be. We're hoping it's not a photo op. We're hoping that it doesn't become just a hollow promise. That's why when I said we were concerned about pharmacare coming out, one, does it delay getting the rare disease drug strategy out, and two, is it going to fall to the same kinds of issues that our drug strategy has?